Inflammatory processes exacerbate degenerative neurological disorders

Current Hypotheses and Research Milestones in Alzheimer's Disease

Volumn , Issue , 2009, Pages 117-124

  McGeer, Patrick L ^a   McGeer, Edith G ^a   Schwab, Claudia ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Age related macular degeneration; Alzheimer's disease; Atheroscelorsis; Autoimmunity; Autotoxicity; Diabetes; Innate immune system; Microglia; Parkinson's disease

Indexed keywords

EID: 84900107146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-87995-6_10     Document Type: Chapter

References (30)

1. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22: 799-809
2. McGeer PL, McGeer EG (2000) Autotoxicity and Alzheimer disease. Arch Neurol 57: 789-790
3. McGeer PL, Itagaki S, Tago H. et al. (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79: 195-200
4. Rogers J, Luber-Narod J, Styren SD. et al. (1988) Expression of immune system-Associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9: 339-349
5. McGeer PL, Akiyama H, Itagaki S. et al. (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107: 341-346
6. Rogers J, Cooper NR, Webster S. et al. (1992) Complement activation by beta-Amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89: 10016-10020
7. Webster S, Lue LF, Brachova L. et al. (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18: 415-421
8. McGeer PL, McGeer EG, Rogers J. et al. (1990) Anti-inflammatory drugs and Alzheimer disease. Lancet 335: 1037
9. In TV, Ruitenberg A, Hofman A. et al. (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345: 1515-1521
10. Stewart WF, Kawas C, Corrada M. et al. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632
11. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28: 639-647
12. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314-1318
13. Van Furth R (1998) Human monocytes and cytokines. Res Immunol 149: 719-720
14. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 76: 550-557
15. Chen H, Zhang M, Hernan MA. et al. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064
16. Esposito E, Di Matteo V, Benigno A. et al. (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205: 295-312
17. Gottlieb JL (2002) Age-related macular degeneration. JAMA 288: 2233-2236
18. Anderson DH, Mullins RF, Hageman GS. et al. (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134: 411-431
19. Penfold PL, Madigan MC, Gillies MC. et al. (2002) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20: 385-414
20. McGeer PL, Sibley J (2005) Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 26: 1199-1203
21. Hageman GS, Anderson DH, Johnson LV. et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102: 7227-7232
22. Biessels GJ, Staekenborg S, Brunner E. et al. (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5: 64-74
23. Dahabada HJL, Colin C, Degaki TL. et al. (2004) Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP). J Biol Chem 279: 42803-42810
24. Janson J, Laedtke T, Parisi JE. et al. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481
25. Arvanitakis Z, Wilson RS, Bienias JL (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666
26. Klegeris A, McGeer PL (2007) Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochemical and Biophysical Research Communications 357: 1096-1099
27. Yasojima K, Schwab C, McGeer EG. et al. (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051
28. Akiyama H, Barger S, Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421
29. Eikelenboom P, Van Gool WA (2004) Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111: 281-294
30. Schwab C, McGeer PL (2008) Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 13: 359-369